Login Register Cart 0
Generic placeholder image

Current Immunology Reviews (Discontinued)

Editor-in-Chief

ISSN (Print): 1573-3955
ISSN (Online): 1875-631X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

COVID-19: Update on Pathogenesis and Treatment Strategies

Author(s): Rakesh K. Chauhan, Pramod K. Sharma and Shikha Srivastava*

Volume 16, Issue 1, 2020

Page: [1 - 5] Pages: 5

DOI: 10.2174/1573395516999201001154837

Price: $65

Abstract

COVID-19 (Coronavirus disease) is the most contagious virus, which has been characterized as a global pandemic by WHO. The pathological cycle of COVID-19 virus can be specified as RNAaemia, severe pneumonia, along with the Ground-glass opacity (GGO), and acute cardiac injury. The S protein of Coronavirus has been reported to be involved in the entry of the virus into the host cell, which can be accomplished by direct membrane fusion between the virus and plasma membrane. In the endoplasmic reticulum or Golgi membrane, the newly formed enveloped glycoproteins are introduced. The spread of disease occurs due to contact and droplets unleashed by the vesicles holding the virus particles combined with the plasma membrane to the virus released by the host. The present manuscript describes the pathogenesis of COVID-19 and various treatment strategies that include drugs such as chloroquine and hydroxychloroquine, an anti-malarial drug, antibodies: SARS-CoV-specific human monoclonal antibody CR3022 and plasma treatment facilitate the therapeutic effect.

Keywords: COVID-19, pathogenesis, treatment, therapeutic effect, antiviral drugs, plasma therapy.

Next »
Graphical Abstract

[1]
Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020; 109: 102433.
[http://dx.doi.org/10.1016/j.jaut.2020.102433] [PMID: 32113704]
[2]
Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet 2020; 395(10231): 1225-8.
[http://dx.doi.org/10.1016/S0140-6736(20)30627-9] [PMID: 32178769]
[3]
Ge H, Wang X, Yuan X, et al. The epidemiology and clinical information about COVID-19. Eur J Clin Microbiol Infect Dis 2020; 39(6): 1011-9.
[4]
Lai CC, Ko WC, Lee PI, Jean SS, Hsueh PR. Extra-respiratory manifestations of COVID-19. Int J Antimicrob Agents 2020; 56(2): 106024.
[5]
Malik JK, Kumar A, Soni H. Epidemiology of Novel Corona Virus (Covid-19): A Review. J Clin/Pharmaco Epidemiol 2020; 2: 5-13.
[6]
Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal 2020; 10(2): 102-8.
[http://dx.doi.org/10.1016/j.jpha.2020.03.001] [PMID: 32282863]
[7]
Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation and treatment coronavirus (COVID-19). InStatpearls [internet] . StatPearls Publishing 2020.
[8]
Conti P, Ronconi G, Caraffa A, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents 2020; 34(2): 327-31.
[PMID: 32171193]
[9]
Angeletti S, Benvenuto D, Bianchi M, Giovanetti M, Pascarella S, Ciccozzi M. COVID-2019: The role of the nsp2 and nsp3 in its pathogenesis. J Med Virol 2020; 92(6): 584-8.
[http://dx.doi.org/10.1002/jmv.25719] [PMID: 32083328]
[10]
https://www.uptodate.com/contents/coronavirus-disease-2019- covid-19-hypercoagulability
[11]
Wadman M, Couzin-Frankel J, Kaiser J, Matacic C. A rampage through the body. Science 2020; 368(6489): 356-60.
[12]
Shoenfeld Y. Corona (COVID-19) time musings: Our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning. Autoimmun Rev 2020; 19(6): 102538.
[http://dx.doi.org/10.1016/j.autrev.2020.102538] [PMID: 32268212]
[13]
Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020; 14(1): 72-3.
[http://dx.doi.org/10.5582/bst.2020.01047] [PMID: 32074550]
[14]
Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents 2020; 55(5): 105955.
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105955] [PMID: 32234468]
[15]
Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents 2020; 105932 (10.1016).
[16]
Singh AK, Singh A, Shaikh A, Singh R, Misra A. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes Metab Syndr 2020; 14(3): 241-6.
[http://dx.doi.org/10.1016/j.dsx.2020.03.011] [PMID: 32247211]
[17]
Tian X, Li C, Huang A, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect 2020; 9(1): 382-5.
[http://dx.doi.org/10.1080/22221751.2020.1729069] [PMID: 32065055]
[18]
Available at: https://www.antibodysociety.org/covid-19/
[19]
Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA 2020; 117(17): 9490-6.
[http://dx.doi.org/10.1073/pnas.2004168117] [PMID: 32253318]
[20]
Eastman RT, Roth JS, Brimacombe KR, et al. Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. ACS Cent Sci 2020; 6(5): 672-83.
[http://dx.doi.org/10.1021/acscentsci.0c00489] [PMID: 32483554]

Rights & Permissions Print Cite
Article Metrics
21
1
© 2024 Bentham Science Publishers | Privacy Policy